The SOL-R Study (Age-Related Macular Degeneration) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an investigational implanted drug called Ocular Therapeutix Tyrosine Kinase Inhibitor Axitinib (the study drug) is a safe and effective option for people with nAMD.
Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
¿Quién puede participar en el Estudio?
Adults ages 50+ who:
- Are diagnosed with nAMD
- Have never had eye surgery and do not have any current plans for eye surgery
For more information, contact the study team at DEC_ResearchAdmin@duke.edu.
¿Qué Implica?
If you choose to join this study, you will get a random assignment (by chance) to 1 of 3 groups:
- Group 1: You will get the study drug implanted
- Group 2: You will get 2 mg aflibercept injections (standard drug)
- Group 3: You will get 8 mg aflibercept injections
The study drug implant is made with a gel-like structure that is designed to dissolve in the eye and be resorbed by the body and does not need to be removed.
Participation in the study will last approximately 16.5 months (72 weeks) for each participant. Duration includes up to 24 weeks of screening, 40 weeks of drug regimen, and 8 weeks of follow-up.
Detalles del Estudio
